June 23, 2022
Happy summer everyone!
Here are a few updates:
Legislative Update: Bills of Interest Signed into Law
HB 1780, Drug Takeback was signed into law on June 10, 2022. This bill provides that the Act may be cited as the Drug Take-Back Act. Provides that each covered manufacturer must, beginning January 1, 2024 (rather than no later than July 1, 2022) or 6 months after becoming a covered manufacturer, individually or collectively implement (rather than participate in) an approved drug take-back program. Requires a drug take-back program to provide for the collection, transportation, and disposal of covered drugs. Provides that specified requirements shall be undertaken by a drug take-back program or a covered manufacturer (rather than a manufacturer program operator). Requires the Environmental Protection Agency to provide a 30-day public comment period on drug take-back program proposals and revised proposals during specified 90-day periods. Provides that the reason for the Agency's rejection of a drug take-back program proposal must be provided in the written notification to the manufacturer program operator.
SB 2969 Glucose Monitoring was signed into law on June 15, 2022. This bill provides that a group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed on or after January 1, 2024 (rather than 2023) shall provide coverage for medically necessary continuous glucose monitors for individuals who are diagnosed with type 1 or type 2 diabetes and require insulin for the management of their diabetes (rather than provide coverage for continuous glucose monitors).
Upcoming Conferences and Webinars:
Assessing the Impact of COVID-19
The Healthcare Council and Employment Law Council have an upcoming webinar: Assessing the Impact of COVID-19. This webinar is free for Healthcare Council members - so please register today!
Leaders from the health system, pharmaceutical, insurance and employment industry will assess the impact of COVID-19 on consumers, payors and healthcare providers including the clinical, financial and operational implications.
Where: Virtual (Microsoft Teams)
Date and Time:
● Wednesday June 29th
● 1:30 - 3:00 pm CST
In the News:
Modern Health reported the Supreme Court ruled last week the Department of Health and Human Services does not have the discretion to change 340B reimbursement rates without gathering data on what hospitals pay for outpatient drugs. In general the 340B program grants safety-net providers access to lower-cost prescription drugs.
